Search

Displaying results 1591 - 1600 of 10000 in total
  1. Drug

    Sulfacetamide

    go.drugbank.com/drugs/DB00634
    Approved

    An anti-infective agent that is used topically to treat skin infections and orally for urinary tract infections.

    Mixtures: FML-S, Se 10-5 SsSynonyms: N(1)-Acetyl-4-aminophenylsulfonamide, N(1)-Acetylsulfanilamide
  2. Drug

    Nerofe

    go.drugbank.com/drugs/DB14786
    Investigational

    Nerofe is under investigation in clinical trial NCT03059615 (A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS).

    Synonyms: WWTFFLPSTLWERK, (ALL D)-, TRP-TRP-THR-PHE-PHE-LEU-PRO-SER-THR-LEU-TRP-GLU-ARG-LYS, (ALL D)-
  3. Drug

    Dexloxiglumide

    go.drugbank.com/drugs/DB04856
    Investigational

    Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued. … As the D-isomer of loxiglumide, it retains all pharmacological properties of loxiglumide but is more potent.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  4. Drug

    Sulfadiazine

    go.drugbank.com/drugs/DB00359
    ApprovedInvestigationalVet approved

    One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.

    Mixtures: TMP/S-400 Medicated Premix Powder, ST-480 PowderCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Substrates
  5. Drug

    Dextrose, unspecified form

    go.drugbank.com/drugs/DB09341
    ApprovedInvestigationalVet approved

    It is primarily stored as starch in plants and glycogen in animals to be used in various metabolic processes in the cellular level. … Glucose is listed on the World Health Organization's List of Essential Medicines.

    Mixtures: D-5-S, D-5-1/3 SCategories: Compounds used in a research, industrial, or household setting
  6. Drug

    Betamethasone

    go.drugbank.com/drugs/DB00443
    ApprovedInvestigationalVet approved

    [A192444] It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. … Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties.

    Mixtures: DISON´S DEX, DISON´S DEXCategories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  7. Drug

    Cepeginterferon alfa-2B

    go.drugbank.com/drugs/DB12814
    Investigational

    Cepeginterferon alfa-2B is under investigation in clinical trial NCT01889433 (An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic … Hepatitis C).

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsSynonyms: Cepeginterferon Alfa 2 B, Pegylated human interferon A-2B
  8. Drug

    Pheniramine

    go.drugbank.com/drugs/DB01620
    Approved

    Pheniramine is a first-generation antihistamine in the alkylamine class, similar to [brompheniramine] and [chlorpheniramine]. … [A181628] It is used in some over-the-counter allergy as well as cold & flu products in combination with other drugs.

    Mixtures: OCTILIA ALLERGIA E INFIAMMAZIONE, OCTILIA ALLERGIA E INFIAMMAZIONECategories: Heterocyclic Compounds, 1-Ring
  9. Drug

    Oxycodone

    go.drugbank.com/drugs/DB00497
    ApprovedIllicitInvestigational

    [A178696] It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics … [Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.[L6460]

    Mixtures: OSSICODONE E NALOXONE EG, OSSICODONE E NALOXONE EGCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 Substrates
  10. Drug

    Upadacitinib

    go.drugbank.com/drugs/DB15091
    ApprovedInvestigational

    [L10896] In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration. … [A189171] The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors